Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for atopic dermatitis

Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis Dermira to receive an option exercise fee of $50 MM and additional potential milestone payments and royalties Dermira expects to initiate Phase 3 program by end of 2019

The release as fetched from its publisher. almirall.com ↗